EFFicacious glycaEmia Control, Treatment Goal achIevement Very simplE With NovoMix 30: A Single-country, Multicentre, Prospective, Open Label, Non-controlled, Observational, 26-week Study in Serbian Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Diabetes Mellitus in Everyday Clinical Practice.
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EFFECTIVE
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 24 May 2012 Official Title amended as reported by ClinicalTrials.gov.
- 17 Jul 2009 Actual end date (1 Jun 2009) added as reported by ClinicalTrials.gov.